PapersPMID:30588573
Effects of oral activated charcoal on hyperphosphatemia and vascular calcification in Chinese patients with stage 3-4 chronic kidney disease.
What moved
1 findingHow to read these marks →“However, beginning from the 3rd month, the phosphorus levels of the OAC group started to become lower than that of the placebo group, and remained so until the end of the experiment (t = 3.653, P = 0.000).”
- Study
- RCT
- Duration
- 12 months
- Dose studied
- 0.6-1.2 g each time, three times a day, taken with food
- Population
- Adults with stage 3-4 chronic kidney disease and serum phosphorus in the normal range at entry; phase 1 of the trial, charcoal versus placebo, 12 months
Study record
- Design
- randomised controlled trial
- Species
- human
- Population
- Chinese patients with stage 3-4 chronic kidney disease, Qianfoshan Hospital, Shandong. Phase 1: OAC versus placebo. Phase 2: patients who developed hyperphosphatemia, randomised to OAC, calcium carbonate or lanthanum carbonate
- Participants
- 97
- Comparator
- placebo
- Duration
- 365 days
- Endpoints measured
- 23